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Abstract 
The essential oils from Commiphora species have for centuries been 
recognised to possess medicinal properties. Here we performed gas chromatography?
mass spectrometry (GC?MS) on the essential oil from opoponax (Commiphora 
guidottii) and identified bisabolene isomers as the main constituents of this essential 
oil. Opoponax essential oil, a chemical component; β?bisabolene and an alcoholic 
analogue; α?bisabolol, were tested for their ability to selectively kill breast cancer 
cells.  Only β?bisabolene, a sesquiterpene constituting 5% of the essential oil, 
exhibited selective cytotoxic activity for mouse cells (IC50 in normal Eph4: >200 
µg/ml, MG1361: 65.49 µg/ml, 4T1: 48.99 µg/ml) and human breast cancer cells 
(IC50 in normal MCF10A: 114.3 µg/ml, MCF7: 66.91 µg/ml, MDA?MB?231: 98.39 
µg/ml, SKBR3: 70.62 µg/ml and BT474: 74.3 µg/ml). This loss of viability was due 
to the induction of apoptosis as shown by AnnexinV?Propidium Iodide and 
Caspase3/7 activity assay. β?bisabolene was also effective in reducing the growth of 
transplanted 4T1 mammary tumours in vivo (37.5% reduction in volume by 
endpoint). In summary, we have identified an anti?cancer agent from the essential oil 
of opoponax that exhibits specific cytotoxicity to both human and murine mammary 
tumour cells in vitro and in vivo and this warrants further investigation into the use of 
β?bisabolene in the treatment of breast cancers. 
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Introduction 
 The medicinal properties of natural products have been appreciated since 
ancient times and they remain a rich source for anti?tumour drug discovery (Da Rocha 
et al., 2001). Derivatives of natural compounds currently used to treat breast cancer 
include chemotherapeutic agents such as paclitaxel, a microtubule stabilizing drug  
(Wani et al., 1971). However, there are unwanted side effects associated with 
chemotherapeutics and this warrants the search for targeted therapeutics which exhibit 
cytotoxicity that is more specific towards cancer cells. Several natural compounds 
from a class of molecules termed sesquiterpenes have shown promise by selectively 
inducing apoptosis in cancer cells. These include β?elemene which has been shown to 
exhibit differential anti?tumour properties against non?small?cell lung carcinoma 
(Wang et al., 2005) and cacalol which selectively kills breast cancer cell lines (Liu et 
al., 2011).  
 In a large scale screening study to ascertain the anti?tumour activity of 374 
medicinal herbs from across the globe, it was found that extracts with tumouricidal 
properties were not segregated within particular families or genus of plants. 
Interestingly however, the biblical herbs, myrrh gum from Commiphora molmol and 
opoponax from Commiphora guidottii both exhibited potent cytotoxic properties 
against neuroblastoma cells. Accordingly, both of these herbs were categorized as 
natural products with strongest anti?tumour activity, characterized by EC50 values in 
the range of 0.019?0.528 mg/ml (Mazzio & Soliman, 2009). The efficacy of Myrrh 
gum extracts from Commiphora molmol in inducing cytotoxicity of Ehrlich solid 
tumours in mice has been previously reported (Al?Harbi et al., 1994). In the case of o 
Commiphora guidottii (also known as opoponax, scented myrrh, Sweet myrrh or 
habak haddi), some of its traditional applications involve treatment of wounds, 
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diarrhoea, stomach discomforts and removal of the placenta after childbirth (Thulin, 
1999; Thulin & Claeson, 1991). The components of opoponax have also been 
reported to exhibit pharmacological properties such as smooth muscle relaxing effects 
(Andersson et al., 1997; Claeson et al., 1991) and anti?microbial properties (de 
Rapper et al., 2012).   
In this study, we set out to investigate the cytotoxic properties of opoponax 
essential oil with regards to breast cancer. The constituents of opoponax essential oil 
have been identified for decades (Craveiro et al., 1983; Ishwar & Levi, 1966) and it is 
known to be rich in sesquiterpenes (Baser et al., 2003; Tian & Shi, 1996), naturally?
occurring molecules known to exert anticancer effects (Ahn et al., 2015; Han et al., 
2014; Martins et al., 2014; Pitchai et al., 2014). Among these is bisabolene, the main 
constituent of opoponax of which α, β, and γ isomers constitute more than one third of 
the essential oil.  Noteworthily, the alcoholic analogue of the α?isomer of bisabolene, 
the main component of Matricaria chamomilla essential oil, has selective cytotoxicity 
against glioma cells (Cavalieri et al., 2004) and mammary tumours (Costarelli et al., 
2010); yet the anti?tumour properties of the other chemically related isoforms of 
bisabolene have not been determined until recently. β?bisabolene was found to be the 
major component of the essential oil of leaves from Duguetia gardneriana which 
exhibited potent antitumor properties against melanoma, hepatocellular carcinoma 
and leukemia cells (Rodrigues et al., 2015). However, the efficacy of β?bisabolene 
against breast cancer cells and its potential as an anti?tumour agent in vivo has not 
been investigated. Hence, following primary analysis of the constituents of opoponax, 
the focus of this study was to assess the potential of β?bisabolene as a selective 
therapeutic agent against breast cancers.  
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Materials and Methods 
Materials 
Opoponax (C. guidottii) essential oil was purchased from Sigma?Aldrich (Dorset, 
UK).  β?bisabolene was kindly provided by R C Treat limited (Suffolk,UK) and α?
Bisabolol purchased from KIC Chemicals (New York, USA). All extracts were 
solubilized and diluted in ethanol to obtain working concentrations.  
 
Gas chromatography mass spectrometry (GCMS) analysis 
Opoponax extracts were analysed using a Finnegan GC 8000 gas chromatograph 
equipped with a MD 800 mass selective detector and an AS 800 Finnegan 
autosampler.  For the capillary column, a DB?5 fused silica column (J&W Scientific) 
was used with the following dimensions: 30m x 0.32mm id. and 0.25µm film 
thickness.  The temperature of the oven was programmed from 50°C to 240°C at a 
rate of 3˚C min
?
1 and maintained at this final temperature for two minutes.  The 
helium carrier gas was set at a flow?rate set of 1ml min
?1
, maintained under constant 
pressure while the injector and source temperatures were both set at 260°C.  The mass 
detector was used in the positive electron impact ionisation mode (EI+) using an 
ionisation voltage of 70 eV.  A scan range of 35 to 450 mass units in 0.45 seconds 
was used for acquiring mass spectra with an interscan time of 0.08 seconds. 
 
Cell culture 
4T1, EpH4 and MG1361 murine mammary cancer cell lines along with MCF?10A, 
MCF?7, MDA?MB?231, SKBR3 and BT474 human breast cancer cell lines were 
obtained from ATCC. 4T1, SKBR3 and BT474 cells were grown in RPMI 1640. 
EpH4, MCF?7 and MDA?MB?231 cells were maintained in DMEM while MG1361 
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cells were cultured in L?15 media. All of the respective culture media were 
supplemented with 10% FBS, 1% L?Glutamine and 20 units of Penicillin?
Streptomycin (Invitrogen, UK). For MG1361 cells, media was also supplemented 
with non essential amino acids. MCF?10A cells were cultured in an equal mixture of 
DMEM/F12 media supplemented with 10% horse serum, 1% L?Glutamine, 20 units 
of Penicillin?Streptomycin, 10ug.ml insulin, 100ng/ml cholera toxin, 0.5ug/ml 
hydrocortisone and 20ng/ml EGF.  The cell lines used were between passages 5 to 40 
and maintained at 37
0
C with 5% CO2. 
 
Cell viability assay 
For viability assays, murine cells were plated at a density of 10,000 cells/well and 
human cells were plated at 20,000 cells/well into a 96?well plate. Cells were treated 
24 hours after seeding with respective agents prepared in media. The viability of cells 
in each well was then quantified using Cell Titer Blue (Promega, UK) according to 
manufacturer’s instructions 24 hours after treatment. 
 
Apoptosis assays 
Cell lysates after specified treatments were analysed with Caspase Glo 3/7 assay kit 
(Promega) according to manufacturer’s instructions. Annexin?V/PI analysis was 
performed using Dead Cell Apoptosis Kit (Invitrogen) according to manufacturer’s 
instructions and stained cells were analysed using a BD FACSCanto flow cytometer. 
 
In vivo administration of βbisabolene  
1.12g/kg of the oily compound βbisabolene, solubilised in corn oil, was administered 
intra?peritoneally, two times a week, for two weeks, did not result in any signs of 
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distress in all animals. Upon necropsy, the histology of liver, kidney, spleen and lung 
of these mice appeared normal (data not shown). When a dose of 2.24g/kg was 
administered, mice showed signs of morbidity after single treatment. Hence, we used 
a maximum non?lethal dose of 1.12g/kg β?bisabolene in our tumour growth studies. 
The treatment regime consisted of intra?peritoneal (i.p.) injections twice weekly, once 
palpable tumour were detected (at 2 weeks) and until mice have reached the endpoint 
of the experiment or showed signs of morbidity.   
 
Orthotopic cell transplants and tumour measurements  
All animal experiments were conducted in accordance with the UK Animals 
(Scientific Procedures) Act 1986, under Home Office licence 30/2849. 4T1 cells were 
trypsinized and dissociated into single cell suspensions before transplantation into the 
abdominal mammary fat pads of wild type BALB/C mice which were between 8?12 
weeks old. Mice were then checked for palpable tumours and the resulting tumours 
were measured using calipers three times weekly. At appropriate experimental 
endpoints, tumour, mammary gland, lung and liver tissues were harvested. Tissue 
samples were then fixed in 4% formaldehyde at 4
0
C overnight before processing for 
histological analysis. 
 
Immunohistology 
Fixed tissues were embedded in paraffin, sectioned into 5Tm slices, mounted onto 
poly?L?lysine coated slides and stained with haematoxylin and eosin (H&E). 
Antibodies for cleaved caspase?3 (Cell Signaling Technologies) and Ki?67 
(VectorLabs) were used for immunohistology according to manufacturer’s 
instructions. 
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Statistical analysis 
Data were presented as means of at least three replicates with standard error of the 
mean. Significance was determined by a two?tailed t?test, where p<0.05 was taken as 
the threshold for significance. 
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Results  
GCMS analysis of opoponax essential oil  
In order to better understand the molecular basis of the anti?tumour properties 
of Opoponax, we analyzed the composition of essential oil extracts by GC?MS to 
verify the nature of the chemical components present.  As previously reported (Baser 
et al., 2003; Ishwar & Levi, 1966; Tian & Shi, 1996), we found that trans?β?ocimene, 
α?santalene and α?bisabolene were the main constituents in opoponax (Figure 1a).  
The bisabolenes with α, β and γ isomers, together comprised the major class of 
constituents (36% of the components present in opoponax essential oil extract) with 
α?bisabolene being the most abundant isomer.  The alcoholic analogue α?bisabolol, 
had previously been shown to inhibit the formation of mammary tumours in a mouse 
model of HER2?positive breast cancer and more recently, β?bisabolene was reported 
to be the major component of Duguetia gardneriana essential oil which exhibits anti?
tumour properties. In order to test the efficacy of β?bisabolene against breast cancer 
cells, we obtained a commercial fraction of this next most abundant bisabolene isomer 
in Opoponax, and confirmed its purity, chemical structure and its relationship to the 
original opoponax fraction by GC?MS (Figure 1). The β?bisabolene component 
identified in opoponax essential oil eluted at a retention of 34.4 minutes identical to 
that of the commercially available β?bisabolene standard.  EI mass spectra of the 
identified β?bisabolene, in the essential oil extract and the commercially available 
standard were identical, revealing a base peak at m/z 69, a prominent signal at m/z 93 
and a molecular ion at m/z 204, in good agreement with published literature (Figure 
1b) (Craveiro et al., 1983).  
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βbisabolene treatment decreases the viability of mammary cancer cell lines 
In order to gauge the anti?cancer properties of β?bisabolene, we compared it 
with the crude parental essential oil extract, opoponax and the previously studied 
analogue, α?bisabolol (Cavalieri et al., 2004; Costarelli et al., 2010). We treated a 
tumourigenic (4T1) and a non?tumourigenic (EpH4) murine mammary epithelial cell 
line with equivalent concentrations of each purified chemical, and the crude parental 
essential oil extract.  The two purified chemicals displayed distinct cytotoxicity 
profiles, with β?bisabolene rather than α?bisabolol exhibiting preferential cytotoxicity 
in the tumourigenic cell line compared to its non?tumourigenic counterpart (Figure 
2a). Not only did β?bisabolene exhibit the most potent cytotoxicity in tumourigenic 
4T1 cells, it was the least toxic in non?tumorigenic Eph4 cell lines (Figures 2a?b). 
Opoponax induced a marked decline in viability of the non?tumourigenic EpH4 cells, 
resulting in substantial loss of cells in adherent culture, yet it increased the viability of 
the tumourigenic cell line.  The mechanism behind this apparent survival effect is 
unknown and likely relates to other molecular species within the crude essential oil 
extract.  This highlights the complexity of these essential oils and further underscores 
the need to identify the biological properties of the constituent fractions. 
These results led us to investigate further the specificity of β?bisabolene in 
tumour cell lines in vitro and in vivo.  As α?bisabolol had previously displayed anti?
tumour effects on ErbB2
+
 tumours in mice (Costarelli et al., 2010), we assessed the 
toxicity of β? bisabolene in the ErbB2?positive murine cell line, MG1361 (Figure 2c).  
β?bisabolene induced an equivalent loss of viability in both the undifferentiated 
(basal?like) 4T1 and ErbB2
+
 (luminal) MG1361 tumour cell lines (IC50s of 
48.99Tg/ml and 65.49 µg/ml), with complete loss of cell viability achieved at 
100Tg/ml (Figure 2c).  At this concentration no loss in viability was observed in non?
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tumourigenic EpH4 cells (IC50 of >200 µg/ml) (Figure 2c). β?bisabolene also induced 
time dependent decreases in cell viability for 4T1 cells (Figure 2d). A significant 
decrease in viability relative to vehicle control was observed only after 72 hours of 
culture with β?bisabolene and not at earlier time points in this particular experiment. 
Cytotoxicity was also confirmed in a panel of human breast cancer cell lines, 
representing different ER and HER2 status.  ER
+
 and/or HER2
+
 cells with luminal 
characteristics (SKBR3, MCF?7 and BT474) were most sensitive to β?bisabolene 
(IC50s of 70.62Tg/ml, 66.91µg/ml and 74.30µg/ml respectively), while the basal?like 
tumour cell line, MDA?MB?231, was significantly more resistant (IC50 of 98.39ug/ml) 
(Figure 2e).  However these effects were limited to a narrow dose range in human cell 
lines in culture, as the non?tumourigenic cell line, MCF?10A, were also susceptible to 
β?bisabolene at marginally elevated concentrations (IC50 of 114.3Tg/ml). 
 
βbisabolene induces apoptosis in mammary cancer cell lines   
 In order to establish whether β?bisabolene induced an active programmed cell 
death, we performed complementary assays for apoptosis following β?bisabolene 
treatment of tumourigenic cell lines.  Treatment of MDA?MB?231 cells with β?
bisabolene for 18 hours disrupted membrane polarity in a significant proportion of 
cells (Figure 3a).  22% (±5.9%) and 66% (±1.8%) of the cell population bound 
annexin V following treatment with 100Tg/ml and 200Tg/ml β?bisabolene 
respectively (Figure 3b), indicating a dose?responsive increase in apoptosis.  No 
difference in propidium iodide staining was observed over the same timecourse, 
indicating that loss of membrane integrity, a sign of necrotic cell death, was not 
induced by treatment (Figure 3b). A comparative analysis of relative caspase activity 
in tumourigenic versus non?tumourigenic cells was also performed.  Here, caspase 3/7 
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activity was found to be induced by β?bisabolene only in the tumourigenic cell line, 
but not in non?tumourigenic cells (Figure 3c). Thus β?bisabolene specifically induces 
apoptosis in tumourigenic mammary cell lines.  
 
βbisabolene treatment reduces the rate of tumour growth in vivo  
 We next investigated the effect of β?bisabolene on the growth of tumours in 
vivo.  An earlier study had shown that tumour initiation was inhibited by α?bisabolol 
but it was unclear whether growth of existing tumours could be inhibited by 
bisabolene (Costarelli et al., 2010).  Here we tested the effects of β?bisabolene on 
mice bearing pre?established mammary tumours.  
β?bisabolene was administered by intraperitoneal injection into female Balb/C 
mice bearing a single orthotopic tumour of transplanted 4T1 cells after two weeks 
post?transplant. A tolerated dose of twice weekly injections (1.12g/Kg) resulted in a 
significant decrease (37.5% decrease in volume by endpoints) in the growth rate of 
tumours in β?bisabolene treated mice relative to vehicle controls (Figure 4a).  Dosing 
at 100mg/Kg three?times weekly had no significant effect on tumour growth (data not 
shown).  Histology of the tumours from the effective treatment group revealed a 
marked increase in cell death within the β?bisabolene treated tumours (Figure 4b). β?
bisabolene treatment induced a significant increase in cleaved caspase?3 positive cells 
(4.6% versus 1.2% in vehicle controls) indicating that the treatment induces apoptotic 
cell death in 4T1 tumors. (Figure 4c). On the other hand, the number of proliferating 
cells as indicated by Ki?67 staining were reduced (2.6% versus 10.9% in controls) in 
β?bisabolene treated tumors (Figure 4d). Accompanying histology of vital organs and 
tissues within these animals revealed no associated increases in cytotoxicity (data not 
shown).  
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Discussion 
 This study describes the identification of an anti?cancer agent isolated from 
the essential oil opoponax that specifically induces apoptosis in breast cancer cells of 
mouse or human origin.  Opoponax (C. guidotti) has previously been demonstrated to 
have anti?cancer properties but the active constituents of this essential oil had not 
been established (Mazzio & Soliman, 2009).  We identified a minor constituent, the 
sesquiterpine, β?bisabolene, to possess tumour specific pro?apoptotic properties.  
Surprisingly opoponax and α?bisabolol did not share the anticancer properties 
attributed to them in other studies (Cavalieri et al., 2004; Costarelli et al., 2010; 
Mazzio & Soliman, 2009) .  This may be due to the cancer cell type, and in the case 
of α?bisabolol, the fact that we were looking at induction of apoptosis in breast cancer 
cell lines rather than prevention of sporadic tumour formation in vivo.  
 Despite this it was clear that the essential oil contains a number of fractions 
that have distinct cytotoxic properties.  The discovery that β?bisabolene is more 
effective at targeting breast cancer cells compared to α?bisabolol is significant 
because it illustrates the importance of examining both major and minor constituents 
of medicinal extracts for agents with particular medicinal properties suitable for 
specific purposes. The other major constituents of Opoponax essential oil that we 
described were trans?β?ocimene, α?santalene and α?bisabolene. These agents have not 
been shown to possess anti?tumour properties as separate entities on their own and it 
would be interesting to assess their cytotoxic efficacies. 
 It is worth noting that β?bisabolene has recently been described to be the 
major constituent of Duguetia gardneriana essential oil which exhibits cytotoxicity 
against melanoma, hepatocellular carcinoma and leukemia cells (Rodrigues et al., 
2015). However, in the study by Rodrigues et al., they found that β?bisabolene was 
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less effective in inducing cytotoxicity in vitro relative to the essential oil from 
Duguetia gardneriana as a whole. This would suggest that the other components of 
Duguetia gardneriana essential oil have a larger contribution than β?bisabolene 
towards the cytotoxic effects observed. For that reason, they only tested the anti?
tumour effects of Duguetia gardneriana essential oil but not β?bisabolene in vivo. 
Based on the selective cytotoxicity against breast cancer cells by β?bisabolene that we 
observed in vitro, we went on to show for the first time that it possesses anti?tumour 
properties in vivo.  
A recent report describing the pro?apoptotic effects of a closely related isomer, 
γ?bisabolene, in oral squamous cell carcinoma cells suggests that bisabolene isomers 
may share certain chemical features which contribute to their anti?tumour functions 
(Jou et al., 2015). Accordingly, the selective induction of apoptosis in cancer cells that 
we observed were also demonstrated by γ?bisabolene against oral squamous 
carcinoma cells but not normal oral fibroblasts. Mechanistically, γ?bisabolene was 
shown to activate p53 mediated apoptosis through PP1/HDAC2 and ERK signaling 
(Jou et al., 2015). If indeed the bisabolene isomers share a similar mechanism of 
action, the specificity towards cancer cells that we observe may be due to differential 
HDAC2 activity in breast cancer cells. It is possible that the higher levels of HDAC2 
observed in breast cancers (Müller et al., 2013; Roy et al., 2014; Seo et al., 2014) play 
an essential role in mitigating the pro?apoptotic effects of p53 (Harms & Chen, 2007), 
making breast cancer cells more susceptible to inhibition of HDAC2 by bisabolene. It 
will be interesting to address this and compare the efficacies of all bisabolene isomers 
to identify that which is most efficient at inducing apoptosis. 
 We have shown that tumour cells can be successfully targeted in vivo by 
intraperitoneal injection of β?bisabolene. This is a product of the specificity of β?
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bisabolene’s cytotoxicity in the mouse model. Although we only observed an effect 
after more than 3 weeks of treatment in vivo (Figure 4a), this is consistent with the 
fact that we see a time?dependent response for in vitro cytotoxicity assays (Figure 2d). 
The dose applied in our in vivo studies (1.12 g/kg) were about ten times less than the 
reported oral LD50 in mice (>13.36g/kg) (Hoffman?LaRoche, 1967b). The oral LD50 
in rats have also been reported to be >5g/kg (Moreno, 1974), indicating that the doses 
we used are within the sub?toxic range. Nonetheless, it may be possible to alter the 
dosing regimen such that the concentration of bisabolene administered is reduced but 
compensated by a higher frequency of doses. Efficacious treatment was achieved with 
twice weekly doses of 1.12g/Kg in our studies.  While a regime of three weekly doses 
at 100mg/Kg exhibited no effect on tumour growth (data not shown), it is conceivable 
that a daily dosing regimen could be both well tolerated and effective at lower doses.  
Additionally, before β?bisabolene is used in a clinical setting, it would be of great 
benefit if its solubility properties in aqueous matrices were significantly enhanced 
through a formulation development exercise.  These optimizations could improve the 
potential clinical benefits of β?bisabolene as a therapeutic in breast cancers.  
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Figure legends 
Figure 1. GCMS analysis of opoponax ethanolic extract and its constituent β
bisabolene. (a) Total ion current (TIC) generated gas chromatogram of the essential 
oil extract of opoponax highlighting its main constituents and the TIC generated gas 
chromatogram of β?bisabolene (inset chromatogram).  The chemical components of 
opoponax essential oil were identified by gas chromatography?mass spectrometry 
(GC?MS), applied in the electron positive (EI +ve) mode.  A number of terpenes 
(mono?and sesquiterpenes) were identified and are listed below according to the peak 
numbers shown in the chromatogram with % peak area data in brackets: 1) cis?α?
ocimene (1.4%), 2) trans?β?ocimene (11.5%), 3) cis?α?bergamotene (2.7%), 4) α?
santalene (21.9), 5) trans?α?bergamotene (9.0%), 6) epi?α?santalene (1.0%), 7) β?
caryophyllene (0.6%), 8) epi?α?Santalene (0.7%), 9) cis?β?farnesene (1.0%), 10) 
curzerene (0.4%), 11) cis?α?bisabolene (27%), 12) β?Bisabolene (5.1%), 13) γ?
bisabolene (3.9%), 14) cis?α?santalol (4.0%) and 15) unknown (0.7%). (b) EI +ve 
mass spectrum of β?bisabolene and its chemical structure (inset). 
 
Figure 2. βbisabolene treatment decreases the viability of mammary cancer cell 
lines. Cells plated in 96?well format and treated with respective compound for 24 
hours. The resulting viability was then quantified as fluorescence and normalized to 
vehicle control treated cells. (a) EpH4 and 4T1 cells treated with opoponax extract, α?
bisabolol or β?bisabolene at a concentration of 50ug/ml for 24 hours. (b) 
Representative images of EpH4 and 4T1 cell after vehicle, α?bisabolol or β?
bisabolene treatment at a concentration of 50ug/ml for 24 hours. (c) Dose response 
curves for EpH4, 4T1 and MG1361 cells treated with varying concentrations of β?
bisabolene. (d) Time course experiment with 4T1 cells treated with vehicle or β?
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bisabolene for 24, 48 or 72 hours. (e) Dose response curves for MCF?10A, MCF?7, 
SKBR3, BT474 and MDA?MB?231 cell lines treated with varying concentrations of 
β?bisabolene. Data points represent triplicates from two independent experiments 
(n=6) ± SEM. **indicates p<0.01, * indicates p<0.05  (two?tailed t?test). 
 
Figure 3. βbisabolene induces apoptosis in mammary cancer cell lines. (a) Flow 
cytometric analysis of MDA?MB?231 cells stained with Annexin?V and propidium 
iodide (PI). Representative dot?plots of MDA?MB?231 cells after treatment with 
increasing concentrations of β?bisabolene. (b) Graph showing the percentage of 
annexin?V
+
 only or annexin?V
+
 PI
+
 populations in MDA?MB?231 cells after treatment 
with β?bisabolene. Data repres nt average of triplicates (n=3) ± SEM. (c) Graph 
showing the levels of caspase 3/7 activity in EpH4 and 4T1 cells after treatment with 
β?bisabolene. Values were normalized against vehicle controls and are means of 
triplicated experiments (n=3) ± SEM. *, *** denotes statistical significance where 
p<0.05 and p<0.001 respectively (two?tailed t?test).      
 
Figure 4. βbisabolene treatment reduces the rate of tumour growth 	. (a) 
Growth curves of 4T1 tumours in Balb/C mice treated with β?bisabolene or vehicle 
control (n=4 for each cohort). Arrow indicates the starting point for treatment. 
*indicates statistical significance, p<0.05 (two tailed t?test). (b) Haematoxylin and 
eosin stained sections of 4T1 tumours from β?bisabolene or vehicle control treated 
mice demonstrating elevated numbers of pyknotic bodies in β?bisabolene treated 
tumours. (c) Immuno?histology for cleaved?caspase 3 staining in 4T1 tumours treated 
with vehicle control or β?bisabolene along with quantification. (d) Immuno?histology 
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for Ki67 staining in 4T1 tumours treated with vehicle control or β?bisabolene along 
with quantification. 
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